Developing a Respiratory Drug for:

Asthma

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Bronchitis

Emphysema

Cystic Fibrosis (CF)

Interstitial Lung Disease (ILD)

Regulation of Nitric Oxide (NO)

Sodium Pyruvate

Phase I/II Study of Mild Asthmatics

Phase I/II Nitric Oxide (NO) Study

Phase I/II Study in Severe COPD Patients

Phase I/II Double Blinded Placebo Controlled Study in Severe COPD Patients

Anti-Viral Effects of Nitric Oxide (NO)

Pyruvate in Cancer Prevention & Treatment

Sarcoidosis


Chronic Bronchitis

Though less well known than emphysema, there are 14 million adult Americans that suffer from chronic bronchitis, which is the ninth-ranking chronic condition in our nation. Like emphysema, many who suffer from it are subject to periodic attacks of obstructed breathing, when airways of the lungs become inflamed and clogged with mucus, often in response to environmental irritants.

According to the most recent study by the National Heart, Lung, and Blood Institute, the prevalence of chronic bronchitis increased in males and females from 1982-1996 and is higher in females than in males. For females, the rate increased about 65 percent (36.3 vs. 59.8 per 1,000) between 1982 and 1996. For males, the rates increased about 50 percent (31.4 vs. 47 per 1,000) over the same period. The difference in the rates was 4.9 per 1,000 in 1982, but increased to 12.1 per 1,000 in 1996 indicating an increase in the disparity by gender.

The FDA has determined that N115 has sufficient safety toxicology and clinical data to proceed with the multi-dose, extended use, clinical trials. Phase II studies will focus on asthmatics and COPD patients. On the basis of existing clinical data, EmphyCorp is confident that its Investigative New Drug, N115, can and will be used for maintenance or continuous treatment of patients over extended periods of time. The Company believes that N115 will set the standard in the pharmaceutical industry for the treatment of major pulmonary diseases.

Home | News | About EmphyCorp | About N115 | N115 Patents | About Lung Diseases | The Market | Contact Us